When what you see is not always what you get: raising the bar of evidence for new diagnostic imaging modalities
Affiliation
Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium; Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK. Electronic address: nora.sundahl@ugent.be.Issue Date
2020
Metadata
Show full item recordAbstract
Even though prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)-computed tomography (CT) is more accurate than conventional imaging in prostate cancer patients, its impact on patient-relevant outcomes is unknown. We argue that more evidence is required before using PSMA-PET-CT as the standard of care for staging.Citation
Sundahl N, Gillessen S, Sweeney C, Ost P. When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities. Eur Urol. 2020.Journal
European UrologyDOI
10.1016/j.eururo.2020.07.029PubMed ID
32847699Additional Links
https://dx.doi.org/10.1016/j.eururo.2020.07.029Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2020.07.029
Scopus Count
Collections
Related articles
- More advantages in detecting bone and soft tissue metastases from prostate cancer using (18)F-PSMA PET/CT.
- Authors: Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE
- Issue date: 2019 Jan-Apr
- New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
- Authors: Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M
- Issue date: 2016 Jul
- (68)Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
- Authors: von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G
- Issue date: 2018 Sep
- Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
- Authors: de Feria Cardet RE, Hofman MS, Segard T, Yim J, Williams S, Francis RJ, Frydenberg M, Lawrentschuk N, Murphy DG, De Abreu Lourenco R
- Issue date: 2021 Mar
- Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.
- Authors: McEwan L, McBean R, Yaxley J, Wong D
- Issue date: 2019 Jun